Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
CareDx says Medicare proposes to maintain reimbursement process for AlloMap » 07:22
10/19/20
10/19
07:22
10/19/20
07:22
CDNA

CareDx

$51.55 /

-0.76 (-1.45%)

CareDx announced that…

CareDx announced that the Centers for Medicare and Medicaid Services recently issued a memo recommending continued coverage of AlloMap through local Medicare Administrative Contractors. AlloMap is widely adopted by physician providers in over 90% of transplant centers across the US, has been the standard of care and incorporated into guidelines by the International Society for Heart and Lung Transplantation since 2010, and is covered by a CPT code which is reimbursed by Noridian, the local MAC in California. The recently issued CMS memo was in response to a request made by a pathologist in January 2013 to make a national coverage determination to non-cover AlloMap. The CMS memo acknowledges that since 2013 there have been multiple studies that have demonstrated the clinical utility of AlloMap, and concludes that continuing the current AlloMap reimbursement process by MACs is clinically appropriate and in the best interests of beneficiaries.

ShowHide Related Items >><<
CDNA CareDx
$51.55 /

-0.76 (-1.45%)

CDNA CareDx
$51.55 /

-0.76 (-1.45%)

10/08/20 BTIG
CareDx price target raised to $55 from $45 at BTIG
10/08/20 Craig-Hallum
CareDx price target raised to $66 from $46 at Craig-Hallum
10/08/20 H.C. Wainwright
CareDx price target raised to $47 from $45 at H.C. Wainwright
10/08/20 Piper Sandler
CareDx price target raised to $62 from $54 at Piper Sandler
CDNA CareDx
$51.55 /

-0.76 (-1.45%)

  • 11
    Jun
CDNA CareDx
$51.55 /

-0.76 (-1.45%)

Over a week ago
On The Fly
Fly Intel: Wall Street's top stories at midday » 12:16
10/08/20
10/08
12:16
10/08/20
12:16
IBM

IBM

$130.70 /

+6.65 (+5.36%)

, MS

Morgan Stanley

$48.91 /

+0.2 (+0.41%)

, EV

Eaton Vance

$60.55 /

+19.54 (+47.65%)

, MCD

McDonald's

$224.42 /

-1.95 (-0.86%)

, DPZ

Domino's Pizza

$401.24 /

-29.9 (-6.94%)

, C

Citi

$44.59 /

-0.25 (-0.56%)

, ATEC

Alphatec

$8.74 /

+1.87 (+27.22%)

, CDNA

CareDx

$51.81 /

+7.98 (+18.21%)

, CYTK

Cytokinetics

$15.38 /

-12.32 (-44.48%)

, AMGN

Amgen

$244.30 /

-13.28 (-5.16%)

, AYI

Acuity Brands

$101.89 /

-11.42 (-10.08%)

Stocks are mildly higher…

ShowHide Related Items >><<
MS Morgan Stanley
$48.91 /

+0.2 (+0.41%)

MCD McDonald's
$224.42 /

-1.95 (-0.86%)

IBM IBM
$130.70 /

+6.65 (+5.36%)

EV Eaton Vance
$60.55 /

+19.54 (+47.65%)

DPZ Domino's Pizza
$401.24 /

-29.9 (-6.94%)

CYTK Cytokinetics
$15.38 /

-12.32 (-44.48%)

CDNA CareDx
$51.81 /

+7.98 (+18.21%)

C Citi
$44.59 /

-0.25 (-0.56%)

AYI Acuity Brands
$101.89 /

-11.42 (-10.08%)

ATEC Alphatec
$8.74 /

+1.87 (+27.22%)

AMGN Amgen
$244.30 /

-13.28 (-5.16%)

IBM IBM
$130.70 /

+6.65 (+5.36%)

09/22/20 UBS
IBM assumed with a Neutral at UBS
08/17/20 JPMorgan
IBM price target raised to $148 from $135 at JPMorgan
07/22/20 Argus
IBM upgraded to Buy from Hold at Argus
07/22/20 Argus
IBM upgraded to Buy from Hold at Argus
MS Morgan Stanley
$48.91 /

+0.2 (+0.41%)

07/20/20 Berenberg
Morgan Stanley price target raised to $45 from $36 at Berenberg
07/17/20 DA Davidson
Morgan Stanley price target raised to $64 from $58 at DA Davidson
07/17/20 Argus
Morgan Stanley price target raised to $60 from $48 at Argus
07/17/20 Barclays
Morgan Stanley price target raised to $60 from $55 at Barclays
EV Eaton Vance
$60.55 /

+19.54 (+47.65%)

10/05/20 Jefferies
Trian involvement could by catalyst for 'beaten down' managers, says Jefferies
10/01/20 Deutsche Bank
Eaton Vance upgraded to Buy on ESG growth potential at Deutsche Bank
09/30/20 Deutsche Bank
Eaton Vance upgraded to Buy from Hold at Deutsche Bank
08/27/20 JPMorgan
JPMorgan upgrades Eaton Vance to Overweight on positive organic growth
MCD McDonald's
$224.42 /

-1.95 (-0.86%)

10/08/20 Wells Fargo
McDonald's Q3 sales show faster than expected recovery, says Wells Fargo
10/08/20 Stephens
Stephens remains positive on U.S. opportunity for McDonald's
10/06/20 Piper Sandler
McDonald's U.K. launch of Beyond burger may be coming, says Piper Sandler
10/01/20 Wells Fargo
McDonald's price target raised to $244 from $222 at Wells Fargo
DPZ Domino's Pizza
$401.24 /

-29.9 (-6.94%)

10/08/20 Stephens
Stephens 'impressed' Domino's has seen 'only modest tapering' in U.S. comps
10/02/20 MKM Partners
Domino's Pizza price target raised to $445 from $385 at MKM Partners
10/01/20 CL King
CL King 'comfortable' with Q3 sales and earnings estimates for Domino's Pizza
10/01/20 UBS
Domino's Pizza price target raised to $430 from $415 at UBS
C Citi
$44.59 /

-0.25 (-0.56%)

10/08/20
Fly Intel: Top five analyst downgrades
10/08/20 JPMorgan
JPMorgan downgrades Citi after 'very disappointing' OCC consent order
10/08/20 JPMorgan
Citi downgraded to Neutral from Overweight at JPMorgan
09/30/20 BofA
Goldman Sachs added to US 1 List, Citi removed at BofA
ATEC Alphatec
$8.74 /

+1.87 (+27.22%)

10/08/20 Lake Street
Alphatec price target raised to $15 from $13 at Lake Street
10/08/20 Canaccord
Alphatec price target raised to $12 from $9 at Canaccord
10/07/20 Piper Sandler
Alphatec's preliminary Q3 revenue 'extraordinary', says Piper Sandler
09/03/20 Cowen
Alphatec initiated with an Outperform at Cowen
CDNA CareDx
$51.81 /

+7.98 (+18.21%)

10/08/20 BTIG
CareDx price target raised to $55 from $45 at BTIG
10/08/20 Craig-Hallum
CareDx price target raised to $66 from $46 at Craig-Hallum
10/08/20 H.C. Wainwright
CareDx price target raised to $47 from $45 at H.C. Wainwright
10/08/20 Piper Sandler
CareDx price target raised to $62 from $54 at Piper Sandler
CYTK Cytokinetics
$15.38 /

-12.32 (-44.48%)

10/08/20 H.C. Wainwright
Cytokinetics price target lowered to $43 from $59 at H.C. Wainwright
10/08/20 Piper Sandler
Piper cuts Cytokinetics target to $25, but buyer on weakness after trial data
10/06/20 Cantor Fitzgerald
Cytokinetics price target raised to $48 from $41 at Cantor Fitzgerald
10/05/20 JMP Securities
MyoKardia takeover highlights value of Cytokinetics' CK-274, says JMP Securities
AMGN Amgen
$244.30 /

-13.28 (-5.16%)

10/08/20 Piper Sandler
Piper remains buyer of Amgen after 'mixed readout' for omecamtiv
10/08/20 Credit Suisse
Mirati Therapeutics price target raised to $190 from $140 at Credit Suisse
10/06/20 Oppenheimer
Amgen price target raised to $280 from $270 at Oppenheimer
AYI Acuity Brands
$101.89 /

-11.42 (-10.08%)

09/16/20 UBS
Acuity Brands initiated with a Sell at UBS
09/15/20 UBS
Acuity Brands initiated with a Sell at UBS
07/01/20 William Blair
William Blair says Acuity margins surprise, still cautious on sustainability
07/01/20 Roth Capital
Roth Capital says checks show Acuity Brands' number 1 customer lost
MS Morgan Stanley
$48.91 /

+0.2 (+0.41%)

MCD McDonald's
$224.42 /

-1.95 (-0.86%)

IBM IBM
$130.70 /

+6.65 (+5.36%)

EV Eaton Vance
$60.55 /

+19.54 (+47.65%)

DPZ Domino's Pizza
$401.24 /

-29.9 (-6.94%)

CYTK Cytokinetics
$15.38 /

-12.32 (-44.48%)

CDNA CareDx
$51.81 /

+7.98 (+18.21%)

C Citi
$44.59 /

-0.25 (-0.56%)

AYI Acuity Brands
$101.89 /

-11.42 (-10.08%)

ATEC Alphatec
$8.74 /

+1.87 (+27.22%)

AMGN Amgen
$244.30 /

-13.28 (-5.16%)

  • 17
    Jul
  • 11
    Jun
MS Morgan Stanley
$48.91 /

+0.2 (+0.41%)

MCD McDonald's
$224.42 /

-1.95 (-0.86%)

IBM IBM
$130.70 /

+6.65 (+5.36%)

EV Eaton Vance
$60.55 /

+19.54 (+47.65%)

DPZ Domino's Pizza
$401.24 /

-29.9 (-6.94%)

C Citi
$44.59 /

-0.25 (-0.56%)

AMGN Amgen
$244.30 /

-13.28 (-5.16%)

MS Morgan Stanley
$48.91 /

+0.2 (+0.41%)

MCD McDonald's
$224.42 /

-1.95 (-0.86%)

IBM IBM
$130.70 /

+6.65 (+5.36%)

EV Eaton Vance
$60.55 /

+19.54 (+47.65%)

DPZ Domino's Pizza
$401.24 /

-29.9 (-6.94%)

CYTK Cytokinetics
$15.38 /

-12.32 (-44.48%)

C Citi
$44.59 /

-0.25 (-0.56%)

AYI Acuity Brands
$101.89 /

-11.42 (-10.08%)

AMGN Amgen
$244.30 /

-13.28 (-5.16%)

MS Morgan Stanley
$48.91 /

+0.2 (+0.41%)

MCD McDonald's
$224.42 /

-1.95 (-0.86%)

IBM IBM
$130.70 /

+6.65 (+5.36%)

DPZ Domino's Pizza
$401.24 /

-29.9 (-6.94%)

C Citi
$44.59 /

-0.25 (-0.56%)

AYI Acuity Brands
$101.89 /

-11.42 (-10.08%)

AMGN Amgen
$244.30 /

-13.28 (-5.16%)

Recommendations
CareDx price target raised to $55 from $45 at BTIG » 08:22
10/08/20
10/08
08:22
10/08/20
08:22
CDNA

CareDx

$43.85 /

+0.68 (+1.58%)

BTIG analyst Sung Ji Nam…

BTIG analyst Sung Ji Nam raised the firm's price target on CareDx to $55 from $45 and keeps a Buy rating on the shares after the company's "impressive" Q3 revenue pre-announcement. The analyst notes "strong performance" across the board in CareDX business, with Testing revenue up 60%, product revenue up 29%, and Digital/Other revenue up 73% from last year. Sung Ji Nam adds that patient access has recovered "significanty" since Q2 while stating that CareDX still has "significant headroom" for strong growth ahead.

ShowHide Related Items >><<
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

CDNA CareDx
$43.85 /

+0.68 (+1.58%)

10/08/20 Craig-Hallum
CareDx price target raised to $66 from $46 at Craig-Hallum
10/08/20 H.C. Wainwright
CareDx price target raised to $47 from $45 at H.C. Wainwright
10/08/20 Piper Sandler
CareDx price target raised to $62 from $54 at Piper Sandler
10/02/20 H.C. Wainwright
CareDx price target raised to $45 from $40 at H.C. Wainwright
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

  • 11
    Jun
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

Recommendations
CareDx price target raised to $66 from $46 at Craig-Hallum » 07:38
10/08/20
10/08
07:38
10/08/20
07:38
CDNA

CareDx

$43.85 /

+0.68 (+1.58%)

Craig-Hallum analyst…

Craig-Hallum analyst Alexander Nowak raised the firm's price target on CareDx to $66 from $46 and keeps a Buy rating on the shares. The analyst notes that CareDx reported preliminary Q3 revenue and test volume well ahead of consensus as "past year/quarter(s) investments are paying off." The performance was clean and Nowak expects sequential growth going into Q4 too.

ShowHide Related Items >><<
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

CDNA CareDx
$43.85 /

+0.68 (+1.58%)

10/08/20 H.C. Wainwright
CareDx price target raised to $47 from $45 at H.C. Wainwright
10/08/20 Piper Sandler
CareDx price target raised to $62 from $54 at Piper Sandler
10/02/20 H.C. Wainwright
CareDx price target raised to $45 from $40 at H.C. Wainwright
10/01/20 Piper Sandler
CareDx entrenched deeper into transplants with Palmetto LCD, says Piper
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

  • 11
    Jun
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

Recommendations
CareDx price target raised to $47 from $45 at H.C. Wainwright » 06:21
10/08/20
10/08
06:21
10/08/20
06:21
CDNA

CareDx

$43.85 /

+0.68 (+1.58%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen raised the firm's price target on CareDx to $47 from $45 and reiterates a Buy rating on the shares. The company reported "robust" sequential growth in Q3, Chen tells investors in a research note.

ShowHide Related Items >><<
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

CDNA CareDx
$43.85 /

+0.68 (+1.58%)

10/08/20 Piper Sandler
CareDx price target raised to $62 from $54 at Piper Sandler
10/02/20 H.C. Wainwright
CareDx price target raised to $45 from $40 at H.C. Wainwright
10/01/20 Piper Sandler
CareDx entrenched deeper into transplants with Palmetto LCD, says Piper
10/01/20 Craig-Hallum
CareDx may receive HeartCare Medicare reimbursement, says Craig-Hallum
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

  • 11
    Jun
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

Recommendations
CareDx price target raised to $62 from $54 at Piper Sandler » 05:16
10/08/20
10/08
05:16
10/08/20
05:16
CDNA

CareDx

$43.85 /

+0.68 (+1.58%)

Piper Sandler analyst…

Piper Sandler analyst Steven Mah raised the firm's price target on CareDx to $62 from $54 and keeps an Overweight rating on the shares after the company reported Q3 preliminary revenue. AlloSure and AlloMap volume for the quarter was 21,800, significantly above the analyst's estimate of 17,737, driven by use of AlloSure in more transplant centers and an increasing number of patients being put on an AlloSure protocol. Mah expects that CareDx's investments into patient care management and digital health solutions will continue to drive organic growth in the future.

ShowHide Related Items >><<
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

CDNA CareDx
$43.85 /

+0.68 (+1.58%)

10/02/20 H.C. Wainwright
CareDx price target raised to $45 from $40 at H.C. Wainwright
10/01/20 Piper Sandler
CareDx entrenched deeper into transplants with Palmetto LCD, says Piper
10/01/20 Craig-Hallum
CareDx may receive HeartCare Medicare reimbursement, says Craig-Hallum
08/06/20 BTIG
CareDx price target raised to $45 from $40 at BTIG
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

  • 11
    Jun
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

On The Fly
Fly Intel: After-Hours Movers » 19:15
10/07/20
10/07
19:15
10/07/20
19:15
ATEC

Alphatec

$6.87 /

+0.11 (+1.63%)

, CDNA

CareDx

$43.85 /

+0.68 (+1.58%)

, REGN

Regeneron

$591.28 /

+9.7 (+1.67%)

, AUY

Yamana Gold

$5.55 /

-0.05 (-0.89%)

, COTY

Coty

$3.33 /

+0.28 (+9.18%)

, VMC

Vulcan Materials

$146.54 /

+5.22 (+3.69%)

, EXFO

Exfo

$3.15 /

-0.01 (-0.32%)

, RGP

Resources Connection

$12.32 /

+0.58 (+4.94%)

, RELL

Richardson Electronics

$4.50 /

+0.18 (+4.17%)

, LAND

Gladstone Land

$15.05 /

-0.54 (-3.46%)

, GLYC

GlycoMimetics

$3.50 /

+0.085 (+2.49%)

, C

Citi

$44.84 /

+0.46 (+1.04%)

Check out this evening's…

ShowHide Related Items >><<
RGP Resources Connection
$12.32 /

+0.58 (+4.94%)

RELL Richardson Electronics
$4.50 /

+0.18 (+4.17%)

REGN Regeneron
$591.28 /

+9.7 (+1.67%)

LAND Gladstone Land
$15.05 /

-0.54 (-3.46%)

GLYC GlycoMimetics
$3.50 /

+0.085 (+2.49%)

EXFO Exfo
$3.15 /

-0.01 (-0.32%)

COTY Coty
$3.33 /

+0.28 (+9.18%)

CDNA CareDx
$43.85 /

+0.68 (+1.58%)

C Citi
$44.84 /

+0.46 (+1.04%)

AUY Yamana Gold
$5.55 /

-0.05 (-0.89%)

ATEC Alphatec
$6.87 /

+0.11 (+1.63%)

ATEC Alphatec
$6.87 /

+0.11 (+1.63%)

09/03/20 Cowen
Alphatec initiated with an Outperform at Cowen
06/18/20 Northland
Alphatec initiated with an Outperform at Northland
06/15/20 Canaccord
Alphatec ready for acceleration into thee second half, says Canaccord
05/12/20 Piper Sandler
Alphatec underlying momentum remains strong, says Piper Sandler
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

10/02/20 H.C. Wainwright
CareDx price target raised to $45 from $40 at H.C. Wainwright
10/01/20 Piper Sandler
CareDx entrenched deeper into transplants with Palmetto LCD, says Piper
10/01/20 Craig-Hallum
CareDx may receive HeartCare Medicare reimbursement, says Craig-Hallum
08/06/20 BTIG
CareDx price target raised to $45 from $40 at BTIG
REGN Regeneron
$591.28 /

+9.7 (+1.67%)

10/07/20 Canaccord
Eli Lilly data further validates COVID antibody therapy, says Canaccord
10/05/20 Cantor Fitzgerald
Regeneron upgraded to Overweight from Neutral at Cantor Fitzgerald
10/05/20 Cantor Fitzgerald
Regeneron upgraded to Overweight from Neutral at Cantor Fitzgerald
09/30/20 Baird
Regeneron Covid data 'bode poorly' for Vir Biotechnology, says Baird
AUY Yamana Gold
$5.55 /

-0.05 (-0.89%)

09/11/20 National Bank
Yamana Gold price target raised to C$9.50 from C$9.25 at National Bank
08/03/20 Peel Hunt
Yamana Gold initiated with a Buy at Peel Hunt
07/24/20 Credit Suisse
Credit Suisse backs Outperform on Yamana Gold after Q2 results
07/20/20 Scotiabank
Yamana downgraded to Sector Perform on valuation at Scotiabank
COTY Coty
$3.33 /

+0.28 (+9.18%)

10/07/20 Jefferies
Coty upgraded to Buy from Hold at Jefferies
09/25/20 Citi
Coty upgraded to Neutral from Sell at Citi
09/24/20
Fly Intel: Top five analyst downgrades
09/24/20 Consumer Edge
Coty downgraded to Equal Weight from Overweight at Consumer Edge
VMC Vulcan Materials
$146.54 /

+5.22 (+3.69%)

10/07/20 Deutsche Bank
Martin Marietta, Vulcan Materials upgraded to Buy at Deutsche Bank
10/07/20 Deutsche Bank
Vulcan Materials upgraded to Buy from Hold at Deutsche Bank
08/06/20
Fly Intel: Top five analyst downgrades
08/06/20 JPMorgan
Vulcan Materials downgraded to Neutral with $145 target at JPMorgan
EXFO Exfo
$3.15 /

-0.01 (-0.32%)

07/09/20 B. Riley Securities
EXFO results positive for Viavi and Dasan, says B. Riley FBR
RGP Resources Connection
$12.32 /

+0.58 (+4.94%)

06/19/20 Sidoti
Resources Connection initiated with a Buy at Sidoti
RELL Richardson Electronics
$4.50 /

+0.18 (+4.17%)

LAND Gladstone Land
$15.05 /

-0.54 (-3.46%)

09/17/20 Berenberg
Gladstone Land initiated with a Buy at Berenberg
09/14/20 Ladenburg
Gladstone Land price target raised to $16.50 from $15.50 at Ladenburg
06/10/20 B. Riley Securities
Gladstone Land price target raised to $17.50 from $16 at B. Riley FBR
12/20/19 Wedbush
Gladstone Land initiated with a Neutral at Wedbush
GLYC GlycoMimetics
$3.50 /

+0.085 (+2.49%)

09/01/20 Roth Capital
GlycoMimetics could become 'interesting' takeout candidate, says Roth Capital
07/31/20 H.C. Wainwright
GlycoMimetics price target lowered to $15 from $16 at H.C. Wainwright
07/22/20 Roth Capital
Roth reiterates Buy on GlycoMimetics after management meeting
06/12/20 Roth Capital
GlycoMimetics analysis of rivipansel study hints at path to approval, Roth says
C Citi
$44.84 /

+0.46 (+1.04%)

09/30/20 BofA
Goldman Sachs added to US 1 List, Citi removed at BofA
09/15/20 Wells Fargo
Citi price target lowered to $66 from $72 at Wells Fargo
09/15/20 Morgan Stanley
Citi's 6% decline more than reflects consent order risk, says Morgan Stanley
09/15/20 Piper Sandler
Citi selloff yesterday on comments, article overdone, says Piper Sandler
VMC Vulcan Materials
$146.54 /

+5.22 (+3.69%)

RGP Resources Connection
$12.32 /

+0.58 (+4.94%)

RELL Richardson Electronics
$4.50 /

+0.18 (+4.17%)

REGN Regeneron
$591.28 /

+9.7 (+1.67%)

LAND Gladstone Land
$15.05 /

-0.54 (-3.46%)

GLYC GlycoMimetics
$3.50 /

+0.085 (+2.49%)

EXFO Exfo
$3.15 /

-0.01 (-0.32%)

COTY Coty
$3.33 /

+0.28 (+9.18%)

CDNA CareDx
$43.85 /

+0.68 (+1.58%)

C Citi
$44.84 /

+0.46 (+1.04%)

AUY Yamana Gold
$5.55 /

-0.05 (-0.89%)

ATEC Alphatec
$6.87 /

+0.11 (+1.63%)

  • 11
    Jun
  • 27
    May
VMC Vulcan Materials
$146.54 /

+5.22 (+3.69%)

REGN Regeneron
$591.28 /

+9.7 (+1.67%)

COTY Coty
$3.33 /

+0.28 (+9.18%)

C Citi
$44.84 /

+0.46 (+1.04%)

VMC Vulcan Materials
$146.54 /

+5.22 (+3.69%)

REGN Regeneron
$591.28 /

+9.7 (+1.67%)

EXFO Exfo
$3.15 /

-0.01 (-0.32%)

COTY Coty
$3.33 /

+0.28 (+9.18%)

C Citi
$44.84 /

+0.46 (+1.04%)

AUY Yamana Gold
$5.55 /

-0.05 (-0.89%)

VMC Vulcan Materials
$146.54 /

+5.22 (+3.69%)

RGP Resources Connection
$12.32 /

+0.58 (+4.94%)

RELL Richardson Electronics
$4.50 /

+0.18 (+4.17%)

REGN Regeneron
$591.28 /

+9.7 (+1.67%)

COTY Coty
$3.33 /

+0.28 (+9.18%)

C Citi
$44.84 /

+0.46 (+1.04%)

AUY Yamana Gold
$5.55 /

-0.05 (-0.89%)

Hot Stocks
CareDx up over 15% at $50.50 per share after guiding Q3 revenue above consensus  17:21
10/07/20
10/07
17:21
10/07/20
17:21
CDNA

CareDx

$43.85 /

+0.68 (+1.58%)

 
ShowHide Related Items >><<
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

CDNA CareDx
$43.85 /

+0.68 (+1.58%)

10/02/20 H.C. Wainwright
CareDx price target raised to $45 from $40 at H.C. Wainwright
10/01/20 Piper Sandler
CareDx entrenched deeper into transplants with Palmetto LCD, says Piper
10/01/20 Craig-Hallum
CareDx may receive HeartCare Medicare reimbursement, says Craig-Hallum
08/06/20 BTIG
CareDx price target raised to $45 from $40 at BTIG
CDNA CareDx
$43.85 /

+0.68 (+1.58%)

  • 11
    Jun
Earnings
CareDx sees Q3 revenue $53M, consensus $44.68M » 16:10
10/07/20
10/07
16:10
10/07/20
16:10
CDNA

CareDx

$43.89 /

+0.72 (+1.67%)

Preliminary revenue for…

Preliminary revenue for the three months ended September 30 is expected to be approximately $53M, an increase of 57% compared with $33.8M in the third quarter of 2019. Testing revenue for the quarter is expected to be approximately $45.2M, compared with $28.2M in the same period in 2019. Total AlloSure and AlloMap patient results provided in the quarter were approximately 21,800. Product revenue in the three months ended September 30, 2020 is expected to be $5.4 million, compared to $4.2M in the same period in 2019. Digital & other revenue in the third quarter of 2020 is expected to be $2.4 million, compared to $1.4 million in the same period in 2019. The preliminary information presented in this press release is based on CareDx's current expectations and may be adjusted as a result of, among other things, completion of customary quarterly review procedures."We continue to invest in growth initiatives to position CareDx as the leader in transplantation and expand our pipeline, including most recently with patient care management and digital solutions," said Reg Seeto, President and Chief Business Officer. "As a result of our strategic investments, we have been able to adapt more efficiently to meet the needs of individual transplant centers during this pandemic and to attract incredible talent to join the CareDx team."

ShowHide Related Items >><<
CDNA CareDx
$43.89 /

+0.72 (+1.67%)

CDNA CareDx
$43.89 /

+0.72 (+1.67%)

10/02/20 H.C. Wainwright
CareDx price target raised to $45 from $40 at H.C. Wainwright
10/01/20 Piper Sandler
CareDx entrenched deeper into transplants with Palmetto LCD, says Piper
10/01/20 Craig-Hallum
CareDx may receive HeartCare Medicare reimbursement, says Craig-Hallum
08/06/20 BTIG
CareDx price target raised to $45 from $40 at BTIG
CDNA CareDx
$43.89 /

+0.72 (+1.67%)

  • 11
    Jun
Hot Stocks
CareDx announces publication of AlloSure lung data » 07:06
10/02/20
10/02
07:06
10/02/20
07:06
CDNA

CareDx

$41.44 /

+3.41 (+8.97%)

CareDx announced the…

CareDx announced the publication of pivotal clinical data for AlloSure Lung in Transplantation Direct and in Biomarker Insights. Transplantation Direct published AlloSure Lung data from the international, multi-center Lung Allograft Rejection Gene expression Observational Study. This study demonstrated that AlloSure Lung could identify patients with acute cellular rejection, a critical need for lung transplant patients whose only option to detect rejection is an invasive bronchoscopy. CareDx has offered AlloSure for lung transplant patients under compassionate use since February 2019 and in June 2020 submitted its AlloSure Lung dossier to Palmetto MolDx for Medicare reimbursement. In the LARGO study, AlloSure Lung results had concurrent lung histopathology that had been assessed by a blinded consensus of an expert pulmonary pathologist panel. A total of 69 unique lung transplant patients from nine centers were examined and included histopathologic diagnoses of allograft infection, normal histopathology without infection, and ACR. The authors concluded that AlloSure Lung holds promise as a non-invasive biomarker of allograft injury with ACR in lung transplant patients. The University of Texas San Antonio experience with AlloSure Lung was published in Biomarker Insights. This publication shared data from a group of 48 patients, in five different cohorts. The patients analyzed varied between three months and 12 years after lung transplantation. The letter from Drs. Deborah Levine, David Ross and Edward Sako supported the concept that further investigation and serial trend monitoring with AlloSure may serve valuable for assessment of lung transplantation allograft dysfunction and to preserve allograft health. These investigators emphasized the value of non-invasive testing with AlloSure Lung is especially high during the COVID-19 pandemic.

ShowHide Related Items >><<
CDNA CareDx
$41.44 /

+3.41 (+8.97%)

CDNA CareDx
$41.44 /

+3.41 (+8.97%)

10/02/20 H.C. Wainwright
CareDx price target raised to $45 from $40 at H.C. Wainwright
10/01/20 Piper Sandler
CareDx entrenched deeper into transplants with Palmetto LCD, says Piper
10/01/20 Craig-Hallum
CareDx may receive HeartCare Medicare reimbursement, says Craig-Hallum
08/06/20 BTIG
CareDx price target raised to $45 from $40 at BTIG
CDNA CareDx
$41.44 /

+3.41 (+8.97%)

  • 11
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.